No Detail Found!

Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS

Author(s)
Zafar Iqbal Division of Pharmaceutical Sciences, Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
Moira Elliott Division of Pharmaceutical Sciences, Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
David G Watson Division of Pharmaceutical Sciences, Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom
Tessa Holyoake Section of Experimental Haematology, Division of Cancer Sciences & Molecular Pathology, University of Glasgow, Royal Infirmary, Glasgow, United Kingdom
Heather Jørgensen Section of Experimental Haematology, Division of Cancer Sciences & Molecular Pathology, University of Glasgow, Royal Infirmary, Glasgow, United Kingdom
Abstract
The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D8-IM) as an internal standard. The biological samples were extracted using Strata- X-C SPE cartridges and separated on C8 column (50 x 3 mm, 3 μm), and methanol: 0.1% formic acid (70:30) was delivered at the rate of 0.7 ml/min as a mobile phase. Imatinib was quantified in samples by monitoring the ions m/z 494.3 for imatinib and 502.3 for D8-imatinib on mass spectrometer. The method was linear in the concentration range of 1-1500 ng/250 μl in spiked human plasma samples and limit of quantification was 5 ng/mL. Inter-day and intra-day variations in spiked human plasma spiked with 50, 250 and 500 ng /mL were less than 3.16%. The repeatability and reproducibility and other parameters of the methods were also validated. The method was employed for the analysis of the imatinib in human plasma and bone marrow samples. The drug levels in bone marrow and plasma samples were correlated to the degree of cytogenetic response. No significant difference of imatinib level between blood and bone marrow in IM-treated patients dosed to steady state was observed.    
Publication Details
Page(s) 285-291
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 24, Issue: 3, Year: 2011

Request the full text from PASTIC

0

Citations

0

Downloads

131

Views